Chantix, Zyban Need Safety Studies In Patients With Mental Illness
FDA's mandate, part of a response to neuropsychiatric adverse events that also includes boxed warnings for the smoking-cessation drugs, follows a trend of requesting sicker patients in trials.
More from Archive
More from Pink Sheet
While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.
Bavarian Nordic's Vimkunya added the US CDC immunization committee's recommendation to its FDA approval, while Valneva's Ixchiq faces a precaution for use in people aged 65 and older.
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.